Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit

MT Newswires Live

2025/11/11

Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.

The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.

With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.

The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.

The comapny's shares were down over 1% in recent trade.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2582306403"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2582306403\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2582306403?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-11 14:43","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2582306403","market":"sh","top_or_hot":-1,"title":"Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit","media":"MT Newswires Live","content":"<html><body><p> Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.</p><p>The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.</p><p>With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.</p><p>The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.</p><p>The comapny's shares were down over 1% in recent trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Granules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nGranules India Arm Gets US FDA Nod for Product from Hyderabad, India Unit\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time smaller\">2025-11-11 14:43</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html><body><p> Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.</p><p>The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.</p><p>With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.</p><p>The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.</p><p>The comapny's shares were down over 1% in recent trade.</p></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU2543165471.USD","symbol_name":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2582306403","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2582306403","pubTimestamp":1762843415,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Granules Life Sciences, a wholly-owned subsidiary Granules India  has received US Food and Drug Administration  approval for a product that was the subject of a pre-approval inspection  at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.The comapny's shares were down over 1% in recent trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU2543165471.USD":"E FUND (HK) GLOBAL QUALITY GROWTH \"A\" (USD) ACC","BK4543":"AI","LU0348723411.USD":"ALLIANZ GLOBAL HI-TECH GROWTH \"A\" (USD) INC","IE00BMPRXR70.SGD":"Neuberger Berman 5G Connectivity A Acc SGD-H","PAI":"Western Asset Income Fund","BK4609":"英伟达持仓股","BK4588":"碎股","BK4141":"半导体产品","IE00BMPRXN33.USD":"NEUBERGER BERMAN 5G CONNECTIVITY \"A\" (USD) ACC","BK4585":"ETF&股票定投概念","PAI.AU":"Platinum Asia Investments Ltd","IE00BMPRXQ63.HKD":"NEUBERGER BERMAN NEXT GENERATION CONNECTIVITY FUND \"A\" (HKDHDG) ACC"},"translate_title":"印度颗粒分公司的产品获得美国FDA批准来自印度海得拉巴子公司的产品","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MNDmain":1.5,"PAI":1,"PAI.AU":1},"content_text":"Granules Life Sciences, a wholly-owned subsidiary Granules India (NSE:GRANULES, BOM:532482) has received US Food and Drug Administration (US FDA) approval for a product that was the subject of a pre-approval inspection (PAI) at its unit in Hyderabad, India, according to a Tuesday filing to the Indian stock exchanges.The inspection was conducted between July 28 and Aug. 1, which conculded with was one observation during that inspection.With this approval, the Granules Life facility is now deemed approved by the US FDA. It is the first approval from the American regulator for the Granules Life site.The same product is already approved and manufactured at Granules' Gagillapur facility and the company plans to launch the approved product in the US market soon.The comapny's shares were down over 1% in recent trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}